Genus PLC Directorate Change (2168K)
23 Agosto 2023 - 10:25AM
UK Regulatory
TIDMGNS
RNS Number : 2168K
Genus PLC
23 August 2023
For Immediate Release
23 August 2023
Genus plc
Non-Executive Director Retirement
Genus plc (LSE: GNS), a leading global animal genetics company,
announces that Lykele van der Broek, Non-Executive Director, has
informed the Company of his intention to step down from the Genus
Board, effective from the conclusion of the 2023 Annual General
Meeting on 22 November 2023, after nine years' service as a
Non-Executive Director.
Russell Reynolds has been retained and is in the process of
identifying potential successors for Lykele.
Commenting on the retirement, Iain Ferguson, Chairman of Genus,
said:
" On behalf of the Board I want to acknowledge Lykele's
significant contributions to the Board's deliberations, bringing to
the fore his experience and knowledge as a leader in growing
agricultural businesses across global markets. We thank him for his
contributions, we will miss his keen insight and business acumen
during our Board discussions and wish him well for the future.
"
For further information please contact:
Genus:
Iain Ferguson, Chairman Tel: +44 (0)1256 345970
Jorgen Kokke, Chief Executive
Buchanan:
Charles Ryland / Chris Lane/ Verity Parker Tel: +44 (0)207 466 5000
About Genus
Genus creates advances to animal breeding and genetic
improvement by applying biotechnology and sells added value
products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently
commercialised by Genus in the dairy, beef and pork food production
sectors.
Genus' worldwide sales are made in over seventy-five countries
under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs)
and comprise semen, embryos and breeding animals with superior
genetics to those animals currently in farms. Genus's customers'
animals produce offspring with greater production efficiency, and
quality, and use these to supply the global dairy and meat supply
chains.
The Group's competitive edge has been created from the ownership
and control of proprietary lines of breeding animals, the
biotechnology used to improve them and its global supply chain,
technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus
companies operate in over twenty-five countries on six continents,
with research laboratories located in Madison, Wisconsin, USA.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGIGDIBDDDGXX
(END) Dow Jones Newswires
August 23, 2023 04:25 ET (08:25 GMT)
Grafico Azioni Genus (LSE:GNS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Genus (LSE:GNS)
Storico
Da Mag 2023 a Mag 2024